PhonlamaiPhoto/iStock via Getty Images
CRISPR Therapeutics (NASDAQ:CRSP) has delayed a much-anticipated Phase 1 trial readout for CTX320, its in vivo gene editing therapy targeting lipoprotein((a)) [Lp((a))], a risk factor associated with major adverse cardiovascular events such as stroke.
In a press release on Thursday, the